与RUNX1、ETV6和ANKRD26胚系变异相关的遗传性血小板疾病
遗传性血小板疾病(HPDs)表型重叠但遗传病因众多,RUNX1、ETV6和ANKRD26的致病性胚系变异还伴随血液系统恶性肿瘤(HM)风险。这三种疾病虽均初始表现为轻中度血小板减少,但HM外显率和恶性发展相关的体细胞改变谱不同。诊断能力提升带来变异评估报告与未发生恶性者的管理和监测挑战,需国际罕见病倡议、变异信息快速共享及高通量功能数据自动化整合等持续技术发展推动及时诊断和白血病预防性治疗干预。
要点
- RUNX1、ETV6和ANKRD26胚系致病变异相关HPDs均伴随血液系统恶性肿瘤风险,但外显率不同。
- 三种疾病初始均可表现为轻中度血小板减少,表型重叠但恶性发展相关体细胞改变谱不同。
- 诊断进步带来变异准确评估报告及未发生恶性者管理和监测的挑战。
核心结论
- RUNX1、ETV6和ANKRD26致病性胚系变异相关的HPDs伴随血液系统恶性肿瘤风险,三者HM外显率和恶性发展相关体细胞改变谱不同。
- 诊断能力提升带来将进展整合入常规临床实践的挑战,需优化未发生恶性者及携带者的管理和监测。
- 国际罕见病倡议、变异信息快速共享和自动化整合变异分类相关数据(如高通量功能数据)的持续技术发展将推动及时诊断和白血病预防性治疗干预。
研究设计与样本
- 本文为综述,汇总RUNX1、ETV6和ANKRD26相关遗传性血小板疾病的遗传病因、恶性风险及诊断管理挑战。
主要发现
- HPDs表型重叠但已知遗传病因众多,促使临床多基因panel的策划与应用,并在 increasingly large-scale populations 中部署以更有效发现缺失的遗传力。
- RUNX1、ETV6和ANKRD26的致病性胚系变异伴随血液系统恶性肿瘤风险,三者HM外显率和恶性发展相关体细胞改变谱不同。
- 三种疾病初始均可表现为相似的轻中度血小板减少。
临床怎么用
- 作者指出,随着HPDs诊断能力改善,面临将进展整合入患者常规临床实践的挑战,以及如何优化未发生恶性者及携带者的管理和监测。
- 作者指出,当前产生的大量遗传信息对准确评估和报告所识别变异构成新挑战。
- 作者认为,国际罕见病倡议、变异信息快速共享及自动化整合变异分类相关数据(如高通量功能数据)的集体进展将推动及时诊断和白血病预防性治疗干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary platelet disorders (HPDs) are a group of blood disorders with variable severity and clinical impact. Although phenotypically there is much overlap, known genetic causes are many, prompting the curation of multigene panels for clinical use, which are being deployed in increasingly large-scale populations to uncover missing heritability more efficiently. For some of these disorders, in particular RUNX1, ETV6, and ANKRD26, pathogenic germ line variants in these genes also come with a risk of developing hematological malignancy (HM). Although they may initially present as similarly mild-moderate thrombocytopenia, each of these 3 disorders have distinct penetrance of HM and a different range of somatic alterations associated with malignancy development. As our ability to diagnose HPDs has improved, we are now faced with the challenges of integrating these advances into routine clinical practice for patients and how to optimize management and surveillance of patients and carriers who have not developed malignancy. The volume of genetic information now being generated has created new challenges in how to accurately assess and report identified variants. The answers to all these questions involve international initiatives on rare diseases to better understand the biology of these disorders and design appropriate models and therapies for preclinical testing and clinical trials. Partnered with this are continued technological developments, including the rapid sharing of genetic variant information and automated integration with variant classification relevant data, such as high-throughput functional data. Collective progress in this area will drive timely diagnosis and, in time, leukemia preventive therapeutic interventions.
引用
- Homan CC, Scott HS, Brown AL, et al. Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26. Blood. 2023. PMID: 36626254. doi:10.1182/blood.2022017735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。